🧬Tidera Health

Tidera provides educational trial discovery tools and does not provide medical advice or determine eligibility. Always discuss options with your care team.

DermatologyICD-10: L50.1

Find Recruiting Clinical Trials for Chronic Spontaneous Urticaria

Search anti-IgE, anti-IL-4/13, and mast cell-targeting trials for CSU — matched to your treatment history.

🔍 Search Chronic Spontaneous Urticaria (CSU) Trials →

About Chronic Spontaneous Urticaria (CSU)

Chronic spontaneous urticaria (CSU) is defined by recurring hives (wheals) and/or angioedema lasting more than 6 weeks without an identifiable external trigger. It affects approximately 1–2% of the population and can cause significant impairment in quality of life. First-line therapy is second-generation antihistamines; omalizumab (Xolair) is the approved biologic for antihistamine-refractory CSU. Novel targets under investigation include anti-IL-4Rα (dupilumab), BTK inhibitors, anti-Siglec-6, and anti-KIT antibodies targeting mast cell activation.

What Types of Chronic Spontaneous Urticaria (CSU) Clinical Trials Exist?

CSU trials test new biologics targeting IgE, mast cell pathways, and cytokine receptors. Many trials require documented antihistamine failure and use the Urticaria Activity Score (UAS7) to confirm active disease. Omalizumab response status often determines eligibility for next-generation trials.

Find Recruiting Chronic Spontaneous Urticaria (CSU) Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Chronic Spontaneous Urticaria (CSU) Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for chronic urticaria?▾
Recruiting CSU trials include studies of dupilumab (IL-4Rα blockade), BTK inhibitors, anti-Siglec-6 antibodies, novel anti-IgE agents, and mast cell stabilizers. Many require prior antihistamine failure and/or omalizumab experience.
What is UAS7 and how does it affect trial eligibility?▾
UAS7 (Urticaria Activity Score over 7 days) is a validated patient-reported tool measuring itch intensity and hive count. Most moderate-to-severe CSU trials require a minimum UAS7 score (typically ≥16) to confirm active disease at enrollment.
Can I join a CSU trial if I already tried omalizumab?▾
Yes — some trials specifically recruit patients who had inadequate response to omalizumab (anti-IgE therapy), seeking patients with persistent symptoms despite maximum approved doses. Others seek omalizumab-naive patients.

Related Conditions

Atopic DermatitisPrurigo NodularisPsoriasis

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.